Acrobiosystems Co Ltd
SZSE:301080

Watchlist Manager
Acrobiosystems Co Ltd Logo
Acrobiosystems Co Ltd
SZSE:301080
Watchlist
Price: 42.81 CNY -3.91% Market Closed
Market Cap: 5.1B CNY
Have any thoughts about
Acrobiosystems Co Ltd?
Write Note
Acrobiosystems Co Ltd
/
Income Statement
/
Revenue

Acrobiosystems Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Acrobiosystems Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Acrobiosystems Co Ltd
SZSE:301080
Revenue
¥543.7m
CAGR 3-Years
30%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
¥17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
¥7.5B
CAGR 3-Years
16%
CAGR 5-Years
84%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
¥5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
¥36.4B
CAGR 3-Years
12%
CAGR 5-Years
31%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
¥2.9B
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

Acrobiosystems Co Ltd
Glance View

Market Cap
5.1B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
50.12 CNY
Undervaluation 15%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Acrobiosystems Co Ltd's Revenue?
Revenue
543.7m CNY

Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Revenue amounts to 543.7m CNY.

What is Acrobiosystems Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
51%

Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Acrobiosystems Co Ltd have been 30% over the past three years , 51% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.